MetaCap

Redhill Biopharma (RDHL) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Traws Pharma is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size. Traws Pharma converts more of its revenue into profit, with a net margin of 328.7% versus -102.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RDHL-40.72%TRAW-63.47%
+26%-21%-68%
Oct 7, 20261 yearNov 20, 2026
RDHL-47.87%TRAW-60.69%
+3%-30%-64%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RDHL versus TRAW key metrics
MetricRDHLTRAW
Share price$0.281$0.175
Market cap$2.50M$2.69M
1-day change-13.08%-23.91%
Forward P/E9.37—
EPS (TTM)$0.00$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.04M$2.79M
Revenue growth (YoY)+23.17%+1134.51%
Net income (latest FY)$-8.27M$9.17M
Gross margin60.31%—
Operating margin-181.69%-640.68%
Net margin-102.80%328.67%
52-week high$1.60$3.23
52-week low$0.281$0.1698
Distance from 52-week high-82.44%-94.58%
Analyst consensus—none
Avg. price target upside—+471.43%
Average volume2.08M610.04K
Shares outstanding8.89M15.37M
Employees134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Traws Pharma is more profitable, keeping 328.7 cents of every revenue dollar as net income versus -102.8 cents for Redhill Biopharma.
  • Traws Pharma grew revenue faster in its latest fiscal year (+1134.51% vs +23.17%).

About Redhill Biopharma

RDHL stock →

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

RDHL vs TRAW FAQ

Which is bigger, Redhill Biopharma or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.50M for Redhill Biopharma (RDHL).

Are Redhill Biopharma and Traws Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons